Introducing The first siRNA technology-based solution for Androgenetic Alopecia, CosmeRNA ARI (SAMiRNA-AR68), designed to address the needs of individuals suffering from this condition.
Bioneer has been dedicated to DNA & RNA R&D, focusing on four Nobel Prize-awarded core technologies in the life sciences field since 1992: DNA sequencing, DNA synthesis, PCR, and siRNA. Patented SAMiRNA serves as an innovative siRNA delivery platform applied to CosmeRNA ARI, utilizing nanoparticle vectors for efficient therapeutic gene delivery. SAMiRNA-AR68 selectively inhibits AR expression in hair follicle cells, a significant factor contributing to androgenetic alopecia, with proven safety and efficacy demonstrated through clinical trials. “CosmeRNA ARI Intensive Hair Tonic,” the advanced formula tailored specifically for medical professionals is on the horizon.